

# ISO 5840-3:2021 (E)

## Cardiovascular implants — Cardiac valve prostheses — Part 3: Heart valve substitutes implanted by transcatheter techniques

---

### Contents

|         |  |
|---------|--|
|         | Foreword   |
|         | Introduction   |
| 1       | Scope  |
| 2       | Normative references   |
| 3       | Terms and definitions  |
| 4       | Abbreviations  |
| 5       | Fundamental requirements                                     |
| 6       | Device description   |
| 6.1     | General  |
| 6.2     | Intended use   |
| 6.3     | Design inputs  |
| 6.3.1   | Operational specifications                                   |
| 6.3.2   | Performance specifications                                   |
| 6.3.2.1 | General  |
| 6.3.2.2 | Transcatheter heart valve system                             |
| 6.3.2.3 | Implantable device   |
| 6.3.2.4 | Delivery system  |
| 6.3.3   | Implant procedure  |
| 6.3.4   | Packaging, labelling and sterilization                       |
| 6.4     | Design outputs   |
| 6.5     | Design transfer (manufacturing verification/validation)      |
| 6.6     | Risk management  |
| 7       | Design verification and validation                           |
| 7.1     | General requirements   |
| 7.2     | In vitro assessment  |
| 7.2.1   | General  |
| 7.2.2   | Test conditions, sample selection and reporting requirements |
| 7.2.3   | Material property assessment                                 |
| 7.2.3.1 | General  |
| 7.2.3.2 | Biological safety  |
| 7.2.3.3 | Material and mechanical property testing                     |
| 7.2.4   | Hydrodynamic performance assessment                          |
| 7.2.5   | Structural performance assessment                            |
| 7.2.5.1 | General  |
| 7.2.5.2 | Implant durability assessment                                |
| 7.2.5.3 | Device structural component fatigue assessment               |
| 7.2.5.4 | Component corrosion assessment                               |
| 7.2.6   | Design- or procedure-specific testing                        |
| 7.2.6.1 | General  |
| 7.2.6.2 | Device migration resistance                                  |
| 7.2.6.3 | Implant foreshortening (length to diameter)                  |
| 7.2.6.4 | Crush resistance   |
| 7.2.6.5 | Recoil   |
| 7.2.6.6 | Radial resistive force (RRF)                                 |
| 7.2.6.7 | Chronic outward force  |

- 7.2.6.8 Delivery system design evaluation requirements
- 7.2.6.9 Visibility
- 7.2.7 Device MRI compatibility
- 7.2.8 Simulated use
- 7.2.9 Human factors and usability assessment
- 7.2.10 Implant thrombogenic and haemolytic potential assessment
- 7.3 Preclinical in vivo evaluation
  - 7.3.1 General
  - 7.3.2 Overall requirements
  - 7.3.3 Methods
  - 7.3.4 Test report
- 7.4 Clinical investigations
  - 7.4.1 General
  - 7.4.2 Study considerations
  - 7.4.3 Study endpoints
  - 7.4.4 Ethical considerations
  - 7.4.5 Pivotal studies: Distribution of subjects and investigators
  - 7.4.6 Statistical considerations including sample size and duration
  - 7.4.7 Patient selection criteria
  - 7.4.8 Valve thrombosis prevention
  - 7.4.9 Clinical data requirements
    - 7.4.9.1 General
    - 7.4.9.2 Baseline
    - 7.4.9.3 Peri-procedure data
    - 7.4.9.4 Follow-up data
    - 7.4.9.5 Clinical investigation analysis and reporting
    - 7.4.9.6 Post-market clinical follow-up

**Annex A (informative) Description of the transcatheter heart valve system**

- A.1 General
- A.2 Description of the transcatheter heart valve substitute
- A.3 Description of delivery system
- A.4 Chemical treatments, surface modifications or coatings
- A.5 Component description
- A.6 Implant procedure

**Annex B (informative) Transcatheter heart valve substitute hazard analysis example**

- B.1 Hazards, foreseeable sequence of events, hazardous situations, and associated harms

**Annex C (informative) Guidelines for verification of hydrodynamic performance — Pulsatile flow testing**

- C.1 General
- C.2 Pulsatile-flow testing
  - C.2.1 General
  - C.2.2 Measuring equipment accuracy
  - C.2.3 Test apparatus requirements
  - C.2.4 Test fixture parameters — Minimum performance testing (for transcatheter aortic valves only)
  - C.2.5 Test fixture parameters — Minimum performance testing (for transcatheter mitral valves only)
  - C.2.6 Test parameters — Multi-range hydrodynamic characterization testing (all transcatheter valves)
  - C.2.7 Test procedure
  - C.2.8 Test report

**Annex D (normative) Requirements for delivery system design and evaluation**

- D.1 General
- D.2 Implant interactions with delivery system
- D.3 Loading of the device into/onto the delivery system
- D.4 Ability to access and deploy

**Annex E (informative) Examples of design specific testing**

- E.1 Stent creep
- E.2 Environmental degradation

- E.3 Static pressure; “burst” test
- E.4 Calcification
- E.5 Particulate generation
- E.6 Effects of device post-dilatation
- E.7 Expansion uniformity
- E.8 Bailout option evaluation
- E.9 Intentional cracking of a pre-existing prosthesis

**Annex F (informative) Preclinical in vivo evaluation**

- F.1 General
- F.2 Disposition of evaluations
  - F.2.1 General
  - F.2.2 Haemodynamic performance
  - F.2.3 Ease of use
  - F.2.4 Device migration or embolization
  - F.2.5 Interference with or damage to adjacent anatomical structures
  - F.2.6 Haemolysis
  - F.2.7 Thrombo-embolic events
  - F.2.8 Calcification/mineralization
  - F.2.9 Pannus formation/tissue ingrowth
  - F.2.10 Structural valve deterioration and non-structural dysfunction
  - F.2.11 Assessment of valve and non-valve related pathology

**Annex G (normative) Adverse event classification during clinical investigation**

- G.1 General
- G.2 Evaluation
- G.3 Data collection requirements
- G.4 Adverse events
- G.5 Adverse device effects
- G.6 Device deficiencies
- G.7 Classification of causal relationships
- G.8 Classification of adverse events
  - G.8.1 General
  - G.8.2 Examples of adverse events
- G.9 Comparison to surgical valve replacement
- G.10 Follow up of SAEs
- G.11 Device-related mortality

**Annex H (informative) Multimodality imaging of TAVI and TMVI pre, peri and post-implantation assessments — Examples**

- H.1 General
- H.2 Multimodality imaging capabilities
- H.3 Echocardiographic (TTE and TEE) data acquisition
- H.4 Computed tomography data acquisition and reconstruction
- H.5 TAVI & TMVR imaging

Page count: 57